Product image of Microgynon 30 Ed (Ethinylestradiol, Levonorgestrel | Lactose) supplied by GNH India

Microgynon 30 Ed

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose
Origin:
EU

Microgynon 30 Ed (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, the active ingredient in Microgynon 30 Ed, is a synthetic estrogen presented as a combined tablet for oral use. It prevents pregnancy in women of reproductive age when taken as directed.
GNH India supplies Microgynon 30 Ed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Microgynon 30 Ed is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.
  • Contraception: provides reliable prevention of pregnancy when taken correctly.
  • Menstrual cycle regulation: helps to regularise bleeding patterns and reduce dysmenorrhoea.
  • Acne management: may improve acne associated with androgen excess.

How It Works

  • Ethinylestradiol and levonorgestrel work together to inhibit the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol suppresses follicle‑stimulating hormone, while levonorgestrel provides progestogenic activity that prevents ovulation, thickens cervical mucus and alters the endometrium, creating an environment unsuitable for fertilisation and implantation.

Side Effects

Microgynon 30 Ed may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea or gastrointestinal discomfort.
  • Breast tenderness or enlargement.
  • Headache or migraine.
  • Breakthrough or spotting bleeding.
  • Weight fluctuation or fluid retention.
  • Mood changes or irritability.

Serious or Rare Side Effects

  • Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism).
  • Arterial thrombosis (stroke, myocardial infarction).
  • Severe hypertension or hypertensive crisis.
  • Hepatic adenoma or benign liver tumours.
  • Allergic reactions (rash, angio‑edema, anaphylaxis).
  • Visual disturbances or sudden loss of vision.

Precautions & Warnings

  • Before prescribing Microgynon 30 Ed, clinicians should assess individual risk factors and counsel patients on safe use.
  • Assess thrombotic risk: evaluate personal and family history of clotting disorders.
  • Screen for cardiovascular disease: avoid in uncontrolled hypertension or recent myocardial infarction.
  • Consider smoking status: contraindicated in women over 35 who smoke.
  • Review liver function: contraindicated in active liver disease or tumours.
  • Pregnancy and lactation: discontinue if pregnancy is confirmed; advise on breastfeeding considerations.
  • Store at room temperature below 25°C: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Microgynon 30 Ed can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) may reduce contraceptive efficacy.
  • Rifampicin or other potent inducers can lower hormone levels.
  • St. John’s wort herbal supplement may compromise protection.
  • Certain protease inhibitors (e.g., ritonavir) can affect hormone metabolism.
  • Antimicrobial agents such as griseofulvin may diminish effectiveness.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., ketoconazole) may increase hormone concentrations.
  • SSRIs or SNRIs can heighten bleeding risk.
  • Antihypertensive drugs (e.g., ACE inhibitors) may require dose adjustment.
  • Ginseng or other herbal stimulants may affect hormone balance.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase cardiovascular risk when combined.

Frequently Asked Questions

Microgynon 30 Ed is a combined oral contraceptive tablet that is used to prevent pregnancy. It is also prescribed to help regulate menstrual cycles, reduce heavy bleeding, and may improve acne associated with hormonal imbalance.

Ethinylestradiol is a synthetic estrogen that suppresses the release of follicle‑stimulating hormone from the pituitary gland. This inhibition, together with the progestogenic action of levonorgestrel, prevents ovulation and creates cervical mucus that is hostile to sperm, thereby reducing the chance of fertilisation.

The dosing regimen for Microgynon 30 Ed is determined by the prescribing healthcare professional. Typically, the product is taken as a daily tablet in a 21‑day active‑pill sequence followed by a 7‑day hormone‑free interval, but the exact schedule should be confirmed with the prescriber.

Microgynon 30 Ed is contraindicated during pregnancy. If pregnancy occurs, the tablet should be stopped immediately. While limited data exist for breastfeeding, most guidelines advise caution; the prescriber will assess the risk‑benefit ratio for each individual.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgynon 30 Ed contains a specific dose of ethinylestradiol and levonorgestrel, offering a balance of estrogen and progestogen that is comparable to other second‑generation combined pills. Its efficacy, side‑effect profile and contraindications are similar, though individual tolerability may vary.

Store Microgynon 30 Ed at room temperature below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Microgynon 30 Ed is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be started on the first day of the menstrual period or as directed by a healthcare professional.

The most serious risks include venous or arterial thromboembolism, severe hypertension, hepatic adenoma, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like chest pain, sudden shortness of breath, severe headache, or visual changes.

Women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or who are pregnant should avoid Microgynon 30 Ed. Additionally, smokers over 35 years of age are contraindicated due to increased cardiovascular risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT